Zevra Therapeutics rises on US FDA approval for rare genetic disease treatment

Zevra Therapeutics

20/09/2024 18:32

** Shares of Zevra Therapeutics  ZVRA.O  rise 1.5% to $8.14 
    ** The U.S. Food and Drug Administration has approved
Zevra's drug for Neimann-Pick disease type C, the first
treatment to get a nod for the rare and fatal genetic condition
    ** The oral drug, Miplyffa, in combination with miglustat,
has been cleared to treat neurological symptoms associated with
NPC in patients 2 years of age and older
    ** ZVRA plans to make the drug available in the U.S. in
eight to 12 weeks
    ** H.C. Wainwright analyst Oren Livnat estimates U.S. peak
sales of about $250 million for Miplyffa 
    ** The FDA had previously declined to approve the drug and
extended its review
    ** Including session's moves, stock up ~27% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com))